Medically-backed: GLP-1s use proven science to help you avoid overeating to lose weight
Axiom Peptides Canada supplies Retatrutide for research and laboratory use only, supporting investigational work focused on GLP-1, GIP, and glucagon receptor pathways
The rest of this article digs into what these drugs actually change in the body the cardiovascular benefits, the metabolic rewiring, the early signals in dementia and cancer, and what the next generation of multi-agonist peptides will look like
Tirzepatide is a once-weekly injectable dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist developed by Eli Lilly
We do not guarantee outcomes but aim to provide context for informed, individualized treatment decisions
Semaglutide titration typically spans 16 weeks with four dose escalations